PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩610 per share · Prices as of the 2026-10-02 close
The company shows an earnings recovery on its modified-drug portfolio and net-cash balance sheet, while generic drug price cuts and low top-line growth remain key variables.
2025 revenue was essentially flat versus 2024, but owner net income increased, signaling an earnings recovery.
In both Q1 and Q2 2026, net income far exceeded operating profit, suggesting a significant impact from non-operating items.
The company has set a 2026 revenue target of KRW 330 billion and a mid-60% modified-drug sales mix to reinforce its defense against drug price cuts.
The phased cut in the generic drug pricing formula and innovative-pharma certification status have emerged as key industry-wide variables in the second half.
On a net-cash balance sheet, shareholder returns continue via treasury share cancellation and dividend increases.
Korea United Pharm is a modified-drug (incrementally modified drug) specialist focused on ethical drugs (ETC), with a core portfolio in cardiovascular and digestive disease treatments.
Key modified drugs driving sales include the antiplatelet agent Cilostan CR, the combination dyslipidemia drug Atmaccombigel, the hypertriglyceridemia drug Omethyl Q-tiret, and the peptic ulcer drug Rabemini, the last of which has surpassed KRW 10 billion in annual sales to join the company's blockbuster lineup.
Pitalic capsule, launched in August 2025, and Silloduo, launched in January 2026, are emerging as new growth products, each generating roughly KRW 600 million in monthly prescription sales.
The company continues to pursue a strategy of raising modified drugs to 60% of total sales, having previously set a target of reaching 70% by 2026.
Its new drug pipeline is developed through affiliate UNS Bio, a joint venture with Seoul National University, targeting P-CAB and both small-molecule and long-acting GLP-1 series compounds.
Internationally, the company exports to more than 40 countries, targeting emerging markets such as the Middle East and the Philippines, while pursuing EU GMP approval for its anticancer drug manufacturing facility to enter the European market.
Overseas sales were around USD 24 million in 2025, with a target of USD 30 million for 2026.
In the competitive landscape, the company competes with traditional domestic pharma players such as Chong Kun Dang, JW Pharmaceutical, and Samjin Pharmaceutical in the generic and modified-drug markets, pursuing a strategy of completing in-house development, clinical trials, and commercialization rather than out-licensing new drug candidates.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩70.4B | ₩10.8B | 15.3% |
| 2025Q3 | ₩74.4B | ₩12.5B | 16.8% |
| 2025Q4 | ₩72.6B | ₩12.5B | 17.3% |
| 2026Q1 | ₩73.8B | ₩11.3B | 15.2% |
| 2026Q2 | ₩77.2B | ₩13.3B | 17.2% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩262.5B | ₩48.2B | ₩45.3B | 18.4% | 13.4% | 23.7% |
| 2023 | ₩278.9B | ₩54.9B | ₩48.3B | 19.7% | 12.7% | 23.8% |
| 2024 | ₩288.7B | ₩56.3B | ₩32.5B | 19.5% | 8.0% | 16.7% |
| 2025 | ₩288.8B | ₩49.6B | ₩38.3B | 17.2% | 8.4% | 14.3% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21
Consolidated 2025 revenue came in at KRW 288.8 billion, essentially flat versus KRW 288.7 billion in 2024, indicating stalled top-line growth. Operating profit fell to KRW 49.6 billion from KRW 56.3 billion a year earlier, with the operating margin declining from 19.5% to 17.2%.
In contrast, owner net income rose to KRW 38.3 billion from KRW 32.5 billion, pointing to an earnings recovery.
Looking at the past four years including 2023 (revenue KRW 278.9 billion, operating margin 19.7%) and 2022 (revenue KRW 262.5 billion, operating margin 18.4%), revenue has grown steadily while the operating margin has passed its peak and eased somewhat.
On a quarterly basis, Q2 2025 revenue was KRW 70.4 billion with operating profit of KRW 10.8 billion, but owner net income was only KRW 1.2 billion; it recovered to KRW 13.5 billion in Q3 and KRW 10.9 billion in Q4.
In Q1 2026, revenue reached KRW 73.8 billion with operating profit of KRW 11.3 billion and net income of KRW 14.0 billion, followed by Q2 2026 revenue of KRW 77.2 billion and operating profit of KRW 13.3 billion.
Notably, Q2 2026 owner net income jumped to KRW 37.7 billion, far outpacing operating profit growth, which appears to reflect a substantial non-operating item, though the specific cause has not yet been clearly confirmed by media or brokerage reports.
As a result, the trailing four-quarter sum (Q3 2025 through Q2 2026) of owner net income reached KRW 76.2 billion, already exceeding the full-year 2025 profit level.
Korea's pharmaceutical industry faces a phased cut in the generic drug pricing formula from 53.55% to 45%.
General pharma companies face this cut by 2029, while innovative-certified companies are given a grace period extending to 2033, making innovative-pharma certification status a key variable determining earnings resilience.
Major traditional pharma companies such as Chong Kun Dang, JW Pharmaceutical, and Samjin Pharmaceutical are reportedly preparing to apply for innovative certification in the second half, and Korea United Pharm is also among the group expected to pursue certification during this period.
The domestic generic drug market is in a phase of decelerating growth amid intensifying competition, prompting a notable shift among pharma companies toward modified-drug-centered portfolios.
Korea United Pharm is responding to these policy and competitive pressures by maintaining and expanding its modified-drug sales mix in the 60% range.
Externally, Middle East instability has been cited as a burden on active pharmaceutical ingredient supply and logistics costs, acting as an industry-wide export and cost risk.
The company has set a 2026 revenue target of KRW 330 billion, aiming for 15% growth even accounting for the headwind of drug price cuts. It continues to pursue a strategy of raising the modified-drug sales mix further from the 60% range to strengthen defenses against policy risk.
Management has noted that companies relying solely on generics could see sales decline by more than 20%, reiterating the defensive value of modified drugs.
New products Pitalic capsule and Silloduo are targeted to reach annual sales of roughly KRW 10 billion and KRW 8 billion, respectively, according to a brokerage estimate as of July 2026, with existing modified drugs also expected to support results.
Overseas sales are targeted to expand from roughly USD 24 million in 2025 to USD 30 million in 2026, alongside efforts to enter the European market via EU GMP approval for its anticancer drug manufacturing facility.
The company plans to pursue innovative-pharma certification in the second half, which would provide a buffer period against generic price cuts if achieved.
Longer term, affiliate UNS Bio is developing new chemical entities in the P-CAB and GLP-1 series, though commercialization remains at an early stage requiring considerable time.
The current share price trades below net asset value per share, placing it in a discount range relative to book value.
On the earnings side, recent quarterly results have shown a recovery trend, and against this backdrop, a brokerage set a target price of KRW 28,000 in an April 13, 2026 report by applying a price-to-earnings multiple of 10 times to its 2026 net income estimate.
That report cited stable growth centered on modified drugs and expectations around innovative-pharma certification as the basis for its target price. Dividends have trended higher in recent years, and shareholder-return measures have also continued, including the cancellation of 423,047 treasury shares in March 2026.
That said, the low revenue growth rate and limited brokerage coverage remain factors constraining broader market attention.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21
With modified drugs accounting for around 60% of sales, the company's defense against generic drug price cuts is viewed as among the strongest in the sector. Beyond existing products like Cilostan CR and Atmaccombigel, new products such as Pitalic capsule and Silloduo are supporting growth. The company is also pursuing innovative-pharma certification in the second half to cushion policy impact.
Owner net income increased in 2025 versus the prior year, and the recovery has continued into 2026 with sustained quarterly net income. In Q2 2026, net income far exceeded operating profit, expanding the overall profit scale. The trailing four-quarter net income total already exceeds full-year 2025 results.
The debt ratio remains at a low level, reflecting a stable financial structure. The company canceled 423,047 treasury shares in March 2026 and has increased dividends in recent years. A structure generating solid annual operating cash flow supports its capacity for shareholder returns.
2025 revenue was essentially flat versus 2024, reflecting stalled top-line growth. Weak domestic consumption and intensifying generic competition are cited as background for the growth slowdown.
With average annual growth staying in the low single digits, market attention lags behind that of new-drug or biotech companies.
A policy phasing down the generic drug pricing formula from 53.55% to 45% is underway, raising concerns about impact on the generic segment, which accounts for a meaningful share of sales. Without innovative-pharma certification, the company would face the full impact of the price cut without a buffer period. If the shift to modified drugs is delayed, margin pressure could widen.
As seen when Q2 2026 net income far exceeded operating profit, quarter-to-quarter net income volatility is significant, and interpretation of results can shift depending on non-operating items. Middle East instability is an external variable that could burden active pharmaceutical ingredient supply and logistics costs. Limited brokerage coverage means relatively greater uncertainty around earnings forecasts.
The phased cut in the generic drug pricing formula is being implemented, and the gap in earnings resilience could widen depending on whether innovative-pharma certification is obtained. Changes in certification review outcomes or detailed implementation schedules could also affect earnings forecasts.
Rising oil prices and logistics costs stemming from Middle East instability could burden active pharmaceutical ingredient supply and costs. Demand fluctuations in emerging export markets such as the Middle East and the Philippines could also affect results.
A recent quarter saw net income expand substantially relative to operating profit, warranting a check on whether the non-operating item is recurring. Limited brokerage coverage means market consensus may have limited statistical representativeness.
Q3 2026 earnings release should be checked to see whether the actual impact of the generic price cut policy is first reflected in results.
Watch for the application and outcome of innovative-pharma certification to see whether a buffer against price cuts is actually secured.
Full-year results will show whether the KRW 330 billion revenue target and the mid-60% modified-drug sales mix goal were achieved.
Check the outcome of EU GMP approval for the anticancer drug manufacturing facility to assess whether entry into the European market becomes tangible.
Korea United Pharm has shown an earnings recovery trend since 2025 on the back of its modified-drug-centered portfolio and net-cash balance sheet, with quarterly net income continuing into 2026.
However, quarterly profit volatility is notable, as seen when Q2 2026 net income far exceeded operating profit, and the full background for this has not yet been fully confirmed.
The generic drug price cut policy, which intensifies from the second half, is a key industry-wide variable, and innovative-pharma certification status is likely to determine earnings resilience.
The company is pursuing multiple strategies in parallel, including expanding the modified-drug mix, launching new products, growing overseas sales, and strengthening shareholder returns. Low revenue growth and limited brokerage coverage remain ongoing challenges.
Q3 earnings, the outcome of innovative-pharma certification, and progress toward the annual target will be important points to watch going forward.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.